U.S. Viscosupplementation Market Analysis

U.S. Viscosupplementation Market Analysis

To get key market trends

  Download Free Sample

Based on product, the market is segmented into single injection, 3 injections, and 5 injections. The 3 injections segment dominated the market with 45.6% of market share in 2023 and is anticipated to experience substantial growth at 7.7% during the analysis time.
 

• The three-injection regimen has been supported by robust clinical evidence demonstrating its effectiveness in relieving symptoms of osteoarthritis and improving joint function. Thus, it has been used as a standard treatment protocol for viscosupplementation for many years.
   
• Moreover, the increasing adoption of three injections can be attributed to its optimal treatment duration, flexibility in dosage and administration, convenient treatment schedule, and widespread clinical acceptance. Owing to these factors, this segment is expected to grow significantly in the forthcoming years.
   

Based on source of origin, the U.S. viscosupplementation market is segmented into avian origin and non-avian origin. The non-avian segment is accounted for significant market share in 2023 and poised to capture the market size of USD 1.6 billion by 2032.
 

• High growth can be attributed to factors such as reduced risk of allergic reactions, ethical and environmental considerations, and the assurance of consistency and purity. Moreover, its broader acceptance in the market contributes to its increasing popularity and adoption in viscosupplementation.
   
• Additionally, as demand for non-animal-derived products continues to rise, non-avian viscosupplements are poised to play an increasingly significant role in meeting patient needs and preferences.
   
• Furthermore, advances in biotechnology and fermentation processes for the production of non-avian products are anticipated to bolster market growth.
   

Based on end-use, the U.S. viscosupplementation market is segmented into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment held majority of market share in 2023 and is predicted to grow at CAGR of 7.5% from 2024 - 2032.
 

• Hospitals offer comprehensive healthcare services, including specialized treatments like viscosupplementation for osteoarthritis. With their broad spectrum of services and resources, hospitals often serve as the primary providers of viscosupplementation therapies, attracting a sizeable patient base seeking orthopedic care.
   
• Additionally, factors such as the rising incidence of osteoarthritis in the U.S., the proliferation of hospitals and clinics, and the availability of advanced medical technologies and equipment further bolster the segment's leading market share.